1-4 of 4
Maria Teresa Herrera-Abreu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer

Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J. Cutts, Heena Shah, Laura Moretti, Lucy S. Kilburn, Hannah Johnson, Iain R. Macpherson, Alistair Ring, Judith M. Bliss, Yingwei Hou, Weiyi Toy, John A. Katzenellenbogen, Sarat Chandarlapaty, Nicholas C. Turner
Journal: Cancer Discovery
Cancer Discov (2024) 14 (2): 274–289.
https://doi.org/10.1158/2159-8290.CD-22-1387
Published: 08 February 2024
View articletitled, ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer
Open the PDF for ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers

Javier Pascual, Joline S.J. Lim, Iain R. Macpherson, Anne C. Armstrong, Alistair Ring, Alicia F.C. Okines, Rosalind J. Cutts, Maria Teresa Herrera-Abreu, Isaac Garcia-Murillas, Alex Pearson, Sarah Hrebien, Heidrun Gevensleben, Paula Z. Proszek, Michael Hubank, Margaret Hills, Jenny King, Mona Parmar, Toby Prout, Laura Finneran, Jason Malia, Karen E. Swales, Ruth Ruddle, Florence I. Raynaud, Alison Turner, Emma Hall, Timothy A. Yap, Juanita S. Lopez, Nicholas C. Turner
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (1): 92–107.
https://doi.org/10.1158/2159-8290.CD-20-0553
Published: 06 January 2021
View articletitled, Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Open the PDF for Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers in another window
Includes: Supplementary data
Journal Articles

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Alex Pearson, Elizabeth Smyth, Irina S. Babina, Maria Teresa Herrera-Abreu, Noelia Tarazona, Clare Peckitt, Elaine Kilgour, Neil R. Smith, Catherine Geh, Claire Rooney, Ros Cutts, James Campbell, Jian Ning, Kerry Fenwick, Amanda Swain, Gina Brown, Sue Chua, Anne Thomas, Stephen R.D. Johnston, Mazhar Ajaz, Katherine Sumpter, Angela Gillbanks, David Watkins, Ian Chau, Sanjay Popat, David Cunningham, Nicholas C. Turner
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (8): 838–851.
https://doi.org/10.1158/2159-8290.CD-15-1246
Published: 01 August 2016
View articletitled, High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Open the PDF for High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer

Maria Teresa Herrera-Abreu, Alex Pearson, James Campbell, Steve D. Shnyder, Margaret A. Knowles, Alan Ashworth, Nicholas C. Turner
Journal: Cancer Discovery
Cancer Discov (2013) 3 (9): 1058–1071.
https://doi.org/10.1158/2159-8290.CD-12-0569
Published: 09 September 2013
View articletitled, Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Open the PDF for Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer in another window
Includes: Supplementary data